BREAKING
Zenas BioPharma, Inc. (ZBIO) Reports a Net Loss for Q4 FY25 6 hours ago Dollar Tree, Inc. (DLTR) Beats Q4 Earnings Estimates 6 hours ago CytomX Therapeutics, Inc. (CTMX) Reports Net Loss for FY25 7 hours ago VNET Group, Inc. (VNET) Q4 2025 Revenue Rises 19.6% 7 hours ago VinFast Auto Ltd. (VFS) Reports a Wider Loss for Q4 FY25 7 hours ago Townsquare Media, Inc. (TSQ) Beats Q4 EPS Estimates 7 hours ago Science Applications International (SAIC) Beats Q4 EPS Estimates 7 hours ago Bitcoin Depot Inc. (BTM) Reports Q4 Earnings 7 hours ago NXP Semiconductors (NXPI) Maintains $1.01 Quarterly Dividend, 2.13% Yield With March 25 Ex-Date 9 hours ago Methanex (MEOH) Stock Plunges 10.9% as Q4 Loss of $0.14/Share Misses Estimate by 121.7% 10 hours ago Zenas BioPharma, Inc. (ZBIO) Reports a Net Loss for Q4 FY25 6 hours ago Dollar Tree, Inc. (DLTR) Beats Q4 Earnings Estimates 6 hours ago CytomX Therapeutics, Inc. (CTMX) Reports Net Loss for FY25 7 hours ago VNET Group, Inc. (VNET) Q4 2025 Revenue Rises 19.6% 7 hours ago VinFast Auto Ltd. (VFS) Reports a Wider Loss for Q4 FY25 7 hours ago Townsquare Media, Inc. (TSQ) Beats Q4 EPS Estimates 7 hours ago Science Applications International (SAIC) Beats Q4 EPS Estimates 7 hours ago Bitcoin Depot Inc. (BTM) Reports Q4 Earnings 7 hours ago NXP Semiconductors (NXPI) Maintains $1.01 Quarterly Dividend, 2.13% Yield With March 25 Ex-Date 9 hours ago Methanex (MEOH) Stock Plunges 10.9% as Q4 Loss of $0.14/Share Misses Estimate by 121.7% 10 hours ago
ADVERTISEMENT
Analysis

Select Medical Reports Mixed Q4 2025 Results as Revenue Growth Offsets Profit Pressures

February 20, 2026 2 min read
Analysis

Select Medical Holdings Corporation (NYSE: SEM), a diversified healthcare services provider, released its Q4 2025 earnings with a blend of strong top-line growth and margin pressure reflecting rising operating costs.

Quarterly Results Overview

However, earnings per diluted share from continuing operations was $0.16, falling short of analysts’ forecast of $0.23 by about 30 %, primarily due to increased costs and lower than expected profitability. Adjusted EBITDA declined to $104.7 million from $116 million in Q4 2024, reflecting margin compression.

Segment Performance and Cost Dynamics

Select Medical’s three core divisions — inpatient rehabilitation hospitals, critical illness recovery hospitals, and outpatient rehabilitation — all contributed positively to revenue growth compared with the prior year.

  • Inpatient rehabilitation hospital revenue increased more than 15 % year-over-year, with improved occupancy and average daily census growth.
  • Critical illness recovery hospitals saw revenue increases and modest EBITDA growth, yet margins remained tight.
  • Outpatient rehabilitation revenue rose driven by increased patient visits, though reimbursement challenges and payer mix shifts pressured average revenue per visit.

Rising health insurance costs emerged as a significant headwind, elevating claims expenses and impacting profitability. Management underscored the ongoing need to balance revenue growth with effective cost management.

Strategic Context and Outlook

Select Medical maintained its strategic focus on expanding its inpatient rehabilitation footprint, with plans to add nearly 400 beds over 2026 and 2027. Despite the EPS miss, management emphasized the diversified nature of the business and the ability of its segments to generate consistent revenue growth.

For the full year 2025, the company generated total revenue of $5.45 billion, with net income and adjusted EBITDA figures underscoring the scale and complexity of operations. Looking ahead, guidance for 2026 projects continued revenue growth of 4 % to 6 % and an increase in adjusted EBITDA, signaling confidence despite near-term cost pressures.

Select Medical’s Q4 results reflect a healthcare services provider managing growth amid reimbursement shifts and operational cost dynamics — a balance that will continue to shape its financial trajectory in 2026.

ADVERTISEMENT